Free Trial
NASDAQ:XOMA

XOMA Royalty Q2 2024 Earnings Report

XOMA Royalty logo
$41.94 -0.01 (-0.02%)
As of 09:47 AM Eastern
This is a fair market value price provided by Massive. Learn more.

XOMA Royalty EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.26
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

XOMA Royalty Revenue Results

Actual Revenue
$11.09 million
Expected Revenue
$8.37 million
Beat/Miss
Beat by +$2.72 million
YoY Revenue Growth
N/A

XOMA Royalty Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
7:45AM ET

Upcoming Earnings

XOMA Royalty's Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules

XOMA Royalty Earnings Headlines

XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend
Physical gold in your 401k - what Wall Street already knows
On March 30th, the Department of Labor quietly filed a rule allowing physical gold to be held inside an eligible 401(k) - a first in the history of the modern retirement system. With $9 trillion in 401(k) savings now potentially eligible, even a small shift in allocation could create a demand wave the gold market has never seen. JPMorgan, Bank of America, and Goldman Sachs are already pricing it in, with gold targets ranging from $5,400 to $6,000 per ounce by end of 2026. There is already an IRS-approved process to move part of an existing 401(k), IRA, or TSP into physical gold - tax-deferred and penalty-free when done correctly.tc pixel
See More XOMA Royalty Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email.

About XOMA Royalty

XOMA Royalty (NASDAQ:XOMA) (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.

View XOMA Royalty Profile